These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36307441)

  • 1. A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs.
    Kobayashi T; Ogawa Y; Shinoda S; Iwaki M; Nogami A; Honda Y; Kessoku T; Imajo K; Yoneda M; Saito S; Yamamoto K; Oeda S; Takahashi H; Sumida Y; Nakajima A
    Sci Rep; 2022 Oct; 12(1):18174. PubMed ID: 36307441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Cassinotto C; Boursier J; Paisant A; Guiu B; Irles-Depe M; Canivet C; Aube C; de Ledinghen V
    Hepatology; 2021 Jun; 73(6):2196-2205. PubMed ID: 33236409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
    J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Canivet CM; Costentin C; Irvine KM; Delamarre A; Lannes A; Sturm N; Oberti F; Patel PJ; Decaens T; Irles-Depé M; Fouchard I; Hermabessière P; Roux M; Barthelon J; Calès P; Powell EE; de Ledinghen V; Boursier J
    Hepatology; 2023 Mar; 77(3):920-930. PubMed ID: 35822302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Mózes FE; Lee JA; Selvaraj EA; Jayaswal ANA; Trauner M; Boursier J; Fournier C; Staufer K; Stauber RE; Bugianesi E; Younes R; Gaia S; Lupșor-Platon M; Petta S; Shima T; Okanoue T; Mahadeva S; Chan WK; Eddowes PJ; Hirschfield GM; Newsome PN; Wong VW; de Ledinghen V; Fan J; Shen F; Cobbold JF; Sumida Y; Okajima A; Schattenberg JM; Labenz C; Kim W; Lee MS; Wiegand J; Karlas T; Yılmaz Y; Aithal GP; Palaniyappan N; Cassinotto C; Aggarwal S; Garg H; Ooi GJ; Nakajima A; Yoneda M; Ziol M; Barget N; Geier A; Tuthill T; Brosnan MJ; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    Gut; 2022 May; 71(5):1006-1019. PubMed ID: 34001645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.
    Tamaki N; Imajo K; Sharpton SR; Jung J; Sutter N; Kawamura N; Yoneda M; Valasek MA; Behling C; Sirlin CB; Kurosaki M; Izumi N; Nakajima A; Loomba R
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):380-387.e3. PubMed ID: 35123096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
    Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
    PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease.
    Lee DH; Sung SU; Lee YK; Lim IH; Jang H; Joo SK; Park JH; Chang MS; So YH; Kim W;
    Aliment Pharmacol Ther; 2022 Apr; 55(8):994-1007. PubMed ID: 35005800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
    Chan WK; Nik Mustapha NR; Mahadeva S
    Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
    Vieira Barbosa J; Lai M
    Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography.
    Kim D; Kim WR; Talwalkar JA; Kim HJ; Ehman RL
    Radiology; 2013 Aug; 268(2):411-9. PubMed ID: 23564711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study.
    Mettananda C; Egodage T; Dantanarayana C; Fernando R; Ranaweera L; Luke N; Ranawaka C; Kottahachchi D; Pathmeswaran A; de Silva HJ; Dassanayake AS
    BMJ Open; 2023 Jan; 13(1):e063959. PubMed ID: 36639212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.